Increased plasma GPNMB levels in patients with parkinson's disease and cognitive impairment.

ABSTRACT: Glycoprotein nonmetastatic melanoma protein B (GPNMB) is a glycosylated type I transmembrane protein that forms soluble GPNMB upon maturation. This study aimed to explore the relationship between plasma GPNMB levels in patients with Parkinson's disease (PD) and their clinical manifestations, as well as their correlations with specific brain regions identified through imaging analysis. This study included patients with PD and healthy control subjects whose plasma GPNMB levels measured by enzyme-linked immunosorbent assay (ELISA). Cognitive function was assessed using the Montreal Cognitive Assessment (MoCA) scale. The imaging analysis employed voxel-based morphometry (VBM) to detect changes in gray matter volume, with the left lentiform nucleus identified as the region of interest (ROI). Th

SUBMITTER: Qi X 

PROVIDER: S-EPMC12214917 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature